Stock price performance of TherapeuticsMD, Inc. is analyzed for various periods using several stock trading signals. The stock price have dropped -10.7% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -15.36% . Looking at the past 52 week period, the stock price is down -8.61% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of TherapeuticsMD, Inc. has a negative value of -9.84 compared to overall market performance. For this week, the average consensus of the company shares are rated as a Strong Buy. The stock has recorded a 20-day Moving Average of 3.58% and the 50-Day Moving Average is 7.72%.The 200 Day SMA reached 20.72%
TherapeuticsMD, Inc. is having a Relative Strength Index of 49.86 which indicates the stock is not yet over sold or over bought based on the technical indicators. Stocks of TherapeuticsMD, Inc. (NYSEMKT:TXMD) rallied by 3.36% during the past week but lost 5.5% on a 4-week basis. The company has outperformed the S&P 500 by 3.24% in the past week but underperformed the index by 6.34% in the last 4 weeks.
Company has reported several Insider transactions to the SEC, on Mar 14, 2016, Cooper C. Collins (director) purchased 16,000 shares at 6.23 per share price.On Aug 27, 2015, Angus C. Russell (director) purchased 13,500 shares at 5.98 per share price.On Aug 24, 2015, Tommy G Thompson (director) purchased 10,798 shares at 6.29 per share price.
TherapeuticsMD Inc Last issued its quarterly earnings results on Nov 3, 2016. The company reported $-0.13 EPS for the quarter, missing the analyst consensus estimate by $ -0.01. Analyst had a consensus of $-0.12. The company had revenue of $5.50 million for the quarter, compared to analysts expectations of $5.64 million. The companys revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.11 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.TherapeuticsMD Inc was Resumed by Jefferies on Nov 22, 2016 to Buy, Price Target of the shares are set at $18.TherapeuticsMD Inc was Initiated by Oppenheimer to Outperform on Nov 22, 2016.
TherapeuticsMD, Inc. (NYSEMKT:TXMD) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.04 points or 0.68% at $5.84 with 1,733,694 shares getting traded. Post opening the session at $5.94, the shares hit an intraday low of $5.78 and an intraday high of $5.98 and the price was in this range throughout the day. The company has a market cap of $1,148 million and the number of outstanding shares has been calculated to be 196,580,210 shares. The 52-week high of TherapeuticsMD, Inc. (NYSEMKT:TXMD) is $9.29 and the 52-week low is $4.39.
TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida.